

**Task History**

June 22, 2011 10:29 PM

**Saved answer set '10581274' opened**

Answer set 7 created with 2 reference answers from CAPLUS

**Detailed display from Answer set 7 of Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors**

# Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors

By: Fox, David J.; Reckless, Jill; Lingard, Hannah; Warren, Stuart; Grainger, David J.

A series of 3-acylaminocaprolactams are inhibitors of chemokine-induced chemotaxis. Branching of the side chain  $\alpha$ -carbon provides highly potent inhibitors of a range of CC and CXC chemokines. The most potent compd. has an ED<sub>50</sub> of 40 pM. Selected compds. were tested in an in vivo inflammatory assay, and the best compd. reduces TNF- $\alpha$  levels with an ED<sub>50</sub> of 0.1  $\mu$ g/kg when administered by either s.c. injection or oral delivery.

## Indexing

Pharmacology (Section 1-3)

## Concepts

Anti-inflammatory agents  
Cell migration  
Chemotaxis  
Human  
Inflammation  
Neutrophil  
Structure-activity relationship  
oral antiinflammatory broad-spectrum chemokine inhibitors

CC chemokines  
CXC chemokines  
Chemokines  
Interleukin 8  
Macrophage inflammatory protein 1 $\alpha$   
Monocyte chemoattractant protein-1  
RANTES(chemokine)  
Tumor necrosis factors  
oral antiinflammatory broad-spectrum chemokine inhibitors  
Biological study, unclassified; Biological study

## Source

Journal of Medicinal Chemistry  
Volume 52  
Issue 11  
Pages 3591-3595  
Journal  
2009  
CODEN: JMCMAR  
ISSN: 0022-2623  
DOI:  
[10.1021/jm900133w](https://doi.org/10.1021/jm900133w)

## Company/Organization

Department of Chemistry  
University of Cambridge  
Cambridge, UK CB2 1EW

## Accession Number

2009:565761  
CAN 151:23962  
CAPLUS

## Publisher

American Chemical Society

## Language

English

## Substances

853905-44-9P  
oral antiinflammatory broad-spectrum chemokine inhibitors  
Drug mechanism of action; Pharmacological activity; Reactant; Synthetic preparation; Therapeutic use;  
Biological study; Preparation; Uses; Reactant or reagent

726187-67-3P  
853905-34-7P  
853905-39-2P  
853905-40-5P  
853905-41-6P  
853905-42-7P  
853905-45-0P  
853905-59-6P  
853905-60-9P  
853905-61-0P  
853905-62-1P  
853905-68-7P  
853905-72-3P  
876063-97-7P  
876063-98-8P  
876063-99-9P  
876064-01-6P  
876064-02-7P  
876064-03-8P  
1160115-32-1P  
1160115-34-3P

oral antiinflammatory broad-spectrum chemokine inhibitors

Drug mechanism of action; Pharmacological activity; Synthetic preparation; Therapeutic use; Biological study; Preparation; Uses

108-18-9 Diisopropylamine  
112-31-2 Decanal  
547-63-7 Methyl isobutyrate  
671-42-1  
870-63-3  
924-50-5 Methyl 3,3-dimethylacrylate  
2094-72-6 1-Adamantanecarbonyl chloride  
2719-27-9 Cyclohexanecarbonyl chloride  
2890-61-1 1-Methylcyclohexanecarbonyl chloride  
3282-30-2 2,2-Dimethylpropionyl chloride  
4301-04-6  
5856-77-9 2,2-Dimethylbutyryl chloride  
15721-22-9 2,2-Dimethylpentanoyl chloride  
19835-38-2  
21568-87-6  
26081-07-2  
28957-33-7  
36278-22-5 1-Cyclohexenecarbonyl chloride  
39482-46-7 2,2-Dimethyl-4-pentenoyl chloride  
39691-62-8 Nonylmagnesium bromide  
50321-59-0  
60631-34-7 2,2-Dimethyldodecanoyl chloride  
67589-90-6  
73152-73-6  
oral antiinflammatory broad-spectrum chemokine inhibitors  
Reactant; Reactant or reagent

2198-82-5P 2,2,5-Trimethyl-4-hexenoic acid  
53663-29-9P (E)-2-Methyldodec-2-enoic acid  
66478-19-1P  
102944-03-6P 3,3-Dimethyldodecanoic acid  
476690-74-3P (E)-Ethyl 2-methyldodec-2-enoate  
853905-71-2P  
1017249-22-7P  
1017249-74-3P

oral antiinflammatory broad-spectrum chemokine inhibitors

Reactant; Synthetic preparation; Preparation; Reactant or reagent

### Supplementary Terms

oral antiinflammatory chemokine inhibitor structure

### Citations

- 1a) Gerard, C; Nat Immunol 2001, 2, 108
- 1b) Horuk, R; Cytokine Growth Factor Rev 2001, 12, 313
- 1c) Rollins, B; Blood 1997, 90, 909
- 1d) Luster, A; N Engl J Med 1998, 338, 436
- 1e) Thelen, M; Nat Immunol 2001, 2, 129
- 2) Viola, A; Annu Rev Pharmacol Toxicol 2006, 46, 171
- 3a) Ribeiro, S; Pharmacol Ther 2005, 107, 44
- 3b) Carter, P; Curr Opin Chem Biol 2002, 6, 510
- 3c) Allen, S; Annu Rev Immunol 2007, 26, 787
- 4a) Vaidehi, N; J Biol Chem 2006, 281, 27613
- 4b) Pasternak, A; Bioorg Med Chem Lett 2008, 18, 1374
- 4c) Santella, L; Bioorg Med Chem Lett 2008, 18, 576
- 4d) Thoma, G; Bioorg Med Chem Lett 2008, 18, 2000
- 5a) Vandercappellen, J; Cancer Lett 2008, 267, 226
- 5b) Biju, P; Bioorg Med Chem Lett 2008, 18, 228
- 6a) Reckless, J; Biochem J 1999, 340, 803
- 6b) Reckless, J; Immunology 2001, 103, 244
- 7a) Fox, D; J Med Chem 2002, 45, 360
- 7b) Fox, D; J Med Chem 2005, 48, 867
- 8a) Grainger, D; Biochem Pharmacol 2003, 65, 1027
- 8b) Naidu, B; Ann Thorac Surg 2003, 75, 1118
- 8c) Wilbert, S; Anal Biochem 2000, 278, 14
- 9) Schroff, R; Mini-Rev Med Chem 2005, 5, 849
- 10) Frow, E; Med Res Rev 2004, 24, 276
- 1) Boyle, W; J Am Chem Soc 1979, 44, 4841
- 2) Rezler, E; J Med Chem 1997, 40, 3508
- 3) Reckless, J; Biochem J 1999, 340, 803
- 4) Fox, D; J Med Chem 2002, 45, 360
- 5) Fox, D; J Med Chem 2005, 48, 867
- 6) Frow, E; Med Res Rev 2004, 24, 267

### Tags

0 Tags

### Comments

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.